EDGE MEDICAL-B(02675.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
EDGE MEDICAL-B
02675.HK
Shenzhen Edge Medical Co., Ltd. engages in designing, developing, manufacturing, and sale of surgical robots in Europe, and China. The company focus on surgical robots and instruments for minimally invasive surgery or MIS, including multi-port endoscopic surgical robots and single-port endoscopic surgical robots. Its products include Edge Multi-Port Endoscopic Surgical Robot, a robot-assisted device that is applied to perform MIS using robotic, imaging, and digital technologies; Edge Single-Port Endoscopic Surgical Robot, a robot-assisted device that is applied to perform MIS through a single small incision or natural orifice; and and Edge Bronchoscope Robot.
178.57 B
02675.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    How far have domestic surgical robots come?

    Zhejiang Merchants Securities research report states that with the implementation of the medical insurance bureau's charging catalog policy and the accelerated expansion of overseas markets, the industry is expected to transition from the early development stage to a rapid growth phase. The medical insurance bureau's charging catalog policy will be implemented in 2026, clearly defining the charging framework for four types of robots, which will significantly lower the admission threshold. Leading companies such as MicroPort and EDGE MEDICAL are experiencing rapid growth in overseas orders, making overseas expansion a new engine for growth. It is expected that by 2032, the market size of surgical robots in China will surge from 7.2 billion yuan in 2024 to 76.7 billion yuan, with a compound annual growth rate of 34%

    Wallstreetcn·
    HK
    02675
    -1.13%
    HK
    02252
    -3.87%
    Wallstreetcn·
    HK
    02675
    -1.13%
    HK
    02252
    -3.87%

    Hong Kong stock movement: EDGE MEDICAL-B rose 12.12%, with clear capital flow; can market sentiment be sustained?

    EDGE MEDICAL-B rose 12.12%; MicroPort Robotics-B rose 14.72%, with a transaction volume of HKD 553 million; MicroPort Medical rose 5.67%, with a transaction volume of HKD 300 million; MicroPort NeuroScience rose 2.01%, with a transaction volume of HKD 58.35 million; Angelalign rose 0.07%, with a market capitalization of HKD 12 billion

    HK Stock Movers Tracker·
    HK
    02675
    -1.13%
    HK Stock Movers Tracker·
    HK
    02675
    -1.13%

    Hong Kong Stock Movement Quick Report: BIOSINO BIO-TEC surged 24.34%, while FSM HOLDINGS and PANGAEA CONNECT both plummeted over 20%

    The market overview of Hong Kong stocks in the past hour shows a clear divergence in market sentiment, with technology and biotechnology sectors performing actively and significant capital inflow. The strong rise of BIOSINO BIO-TEC has led the surge in biotechnology stocks, with an increase of 24.34%. Meanwhile, some small-cap stocks have faced considerable selling pressure, particularly FSM HOLDINGS and PANGAEA CONNECT, both of which fell over 20%. Overall, the short-term heat is changing rapidly, and capital preferences seem to be switching between technology and biotechnology, with increased volatility. Among the stocks with the most significant movements in the past hour, the rise of BIOSINO BIO-TEC is noteworthy, as the 24.34% increase not only attracted a large amount of capital but also boosted the sentiment of the entire biotechnology sector. The active participation of short-term funds has resulted in strong buying interest for this stock during trading, significantly enhancing market heat. Strong stocks: 1. XXF: up 17.16%, with recent market attention rising and significant short-term capital inflow. 2. JINXUN RESOURCE: up 16.13%, benefiting from the overall recovery of the resource sector, with positive capital sentiment. 3. TCL ELECTRONICS: up 15.24%, the strong performance of technology stocks has attracted investors' attention, with sustained short-term heat. 4. EDGE MEDICAL-B: up 10.61%, the activity in the medical sector has made this stock favored by capital, showing steady performance. Under pressure stocks: 1. FSM HOLDINGS: down 20.69%, with market sentiment low and clear short-term capital outflow

    HK Stock Movers Tracker·
    HK
    08247
    +36.00%
    HK
    01721
    0.00%
    HK
    01473
    -5.66%
    HK Stock Movers Tracker·
    HK
    08247
    +36.00%
    HK
    01721
    0.00%
    HK
    01473
    -5.66%

    Morning Trend | EDGE MEDICAL leads the surge with increased volume, and the pharmaceutical sector shows widening divergence

    EDGE MEDICAL-B (2675.HK) saw a significant increase in trading volume yesterday, forming a golden cross on the daily chart, with the MACD opening above the zero line, confirming a short-term bullish pattern. The K-line recorded a strong bullish candle, breaking through the resistance of the 5-day and 10-day moving averages, with significant inflow of main funds, indicating a strong willingness to participate. The pharmaceutical sector is showing high differentiation overall, with structural market conditions and sector rotation intensifying, as market funds tentatively position themselves in emerging innovative drug targets. From a technical perspective, the moving average system shows a bullish arrangement, with strong support built on the short-term technical front; intraday trading volume is active, and there are clear signs of funds clustering. If the volume continues to cooperate, there is a chance to challenge previous highs in the future. However, the divergence within the sector is increasing, and the risk of fund outflow from some high-priced stocks cannot be ignored. In terms of the industry environment, the medical innovative drug sector is supported by policies, driven by research and development progress and performance improvement, attracting long-term funds for increased allocation. Short-term fluctuations are mainly due to the switching of hot topics and the accelerated rhythm of sector rotation, necessitating caution against high-level funds realizing floating profits. Operational advice: Right-side traders should pay attention to the support situation when the price pulls back to the 5-day moving average during the day and participate appropriately in swing opportunities. Monitor the cooperation of main funds and intraday anomalies, and be cautious of the risk of reversal in internal sector sentiment leading to profit-taking. From a medium to long-term perspective, one should carefully assess the matching degree of valuation and fundamentals, and implement dynamic risk management. Industry risks include policy fluctuations, research and development progress falling short of expectations, and high valuation correction pressure. It is crucial to avoid blindly chasing highs in operations, and it is recommended to combine phased position building with stop-loss and take-profit strategies for stable participation

    Technical Forecast·
    HK
    02675
    -1.13%
    Technical Forecast·
    HK
    02675
    -1.13%

    Morning Trend | EDGE MEDICAL-B fluctuates close to the ground, will the medical device main line reappear?

    On January 12th, EDGE MEDICAL-B (2675.HK) continued to oscillate at low levels, with the medical device sector overall trapped in a downward cycle. The industry leaders lack performance, and there is a strong wait-and-see sentiment on the policy front. Throughout the day, the stock price repeatedly consolidated around the support level of 8 HKD, with multiple technical indicators such as MACD, RSI, and Bollinger Bands continuing to weaken, making it difficult to confirm bottom signals. Without the stimulation of collective procurement winning bids or significant new product launches, the sector lacks hotspots. Currently, mainstream funds are withdrawing, and risk appetite is recovering slowly, with small-cap medical device stocks being particularly weak. Right-side opportunities depend solely on policy or innovation-driven factors, such as collective procurement relieving pressure or accelerated approval of innovative drugs, which may lead to a short-term rebound in the sector; otherwise, the existing game of stock will be hard to change. Operational warning: After a prolonged sideways movement, sudden industry events can easily trigger a directional switch. At this stage, it is not advisable to blindly intervene on the left side; it is recommended to track the movements of industry leaders and the latest industry news, and to follow event-driven opportunities in the short term

    Technical Forecast·
    HK
    02675
    -1.13%
    Technical Forecast·
    HK
    02675
    -1.13%
    © 2026 Longbridge｜Disclaimer